CN105327405B - Carried stent and preparation method thereof for treating cervicitis - Google Patents
Carried stent and preparation method thereof for treating cervicitis Download PDFInfo
- Publication number
- CN105327405B CN105327405B CN201510707832.1A CN201510707832A CN105327405B CN 105327405 B CN105327405 B CN 105327405B CN 201510707832 A CN201510707832 A CN 201510707832A CN 105327405 B CN105327405 B CN 105327405B
- Authority
- CN
- China
- Prior art keywords
- cervicitis
- preparation
- carried stent
- liquid
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/146—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses the carried stent and preparation method thereof for treating cervicitis, this method adds a certain amount of NaCl and Ceftriaxone Sodium, mixture is dispersed into uniform liquid by homogenizer predominantly by PLGA adding into dichloromethane.Then aforesaid liquid is slowly dropped in PVA solution, by stirring to get microballoon that is porous and being loaded with Ceftriaxone Sodium, is lyophilized after being rinsed with deionized water to get dry drug bearing microsphere is arrived.Microballoon is placed in cylindrical mold, is put in 70 DEG C of baking oven and keeps the temperature 3 hours, obtain final carried stent.Because the catabolite of PLGA is lactic acid and acetic acid, side effect not will cause to body, and directly act on inflammation part along with the release of drug, have important meaning for the treatment of cervicitis while scaffold degradation.
Description
Technical field
The present invention relates to the preparation methods of cervicitis repair medicine material, and in particular to the load medicine for treating cervicitis
Bracket and preparation method thereof.
Background technique
Cervicitis is a kind of common gynecological disease because canal of uterine cervix mucous epithelium is simple columnar epithelium, easily by
Infection, the general utilization ratio of drug of drug therapy especially oral drugs is lower, and drug is not easy to reach this position, in addition being related to hidden
It the problems such as private, will not generally be cured in time, slowly develop into chronic cervicitis disease.
PLGA is the polymer of lactic acid and hydroxyacetic acid, and the final product of hydrolysis is water and carbon dioxide, intermediate product cream
Acid is also internal normal sugar metabolism product, so the polymer is nontoxic, nonirritant, has good biocompatibility.It is based on
The above-mentioned property of PLGA, therefore PLGA is widely used in the preparation of microballoon, micro-capsule, nanoparticle etc..Therefore, the present invention provides for controlling
Treat the carried stent of cervicitis.
Summary of the invention
It is an object of the invention to overcome deficiencies of the prior art, the load medicine branch for treating cervicitis is provided
Frame and preparation method thereof.
For treating the preparation method of the carried stent of cervicitis comprising the following steps:
(1) PLGA of 0.5~0.8g is dissolved in 5~6ml methylene chloride；
(2) 0.1~0.15gNaCl and the mixing of 0.1~0.15g Ceftriaxone Sodium are weighed, the liquid that step (1) obtains is added to
In body, by homogenizer, 4~5min is stirred with the revolving speed of 4500~5000rpm, so that substance is evenly dispersed in a liquid；
(3) PVA for weighing 2~2.5g is dissolved in 200~220ml deionized water；
(4) step (2) finally obtained mixing liquid is added in the liquid that step (3) obtains, and with 250~
The revolving speed of 350rpm stirs, and stirs 6~8h；
(5) after stirring, thus obtained microsphere is cleaned with deionized water, is then lyophilized；
(6) after being lyophilized, dry microballoon is encased in columnar mould, in 65~70 DEG C of baking oven 2~3h of inside holding, heat preservation
After, obtain the carried stent.
Further implement ground, step (5) wash number for clean thus obtained microsphere with deionized water is 5~8 times.
Further implement ground, the time of step (5) described freeze-drying is 24~36h.
The present invention also provides the carried stents for being used to treat cervicitis as made from the preparation method.Because of the drop of PLGA
Solving product is lactic acid and acetic acid, not will cause side effect to body, and along with the release of drug while scaffold degradation, directly
Inflammation part is acted on, has important meaning for the treatment of cervicitis.
Compared with prior art, present invention has an advantage that
1) PLGA catabolite does not have any side effect, good biocompatibility to bodily tissue；
2) porous microsphere increases porosity, is more advantageous to the release of drug；
3) inflammation part is directly acted on, the utilization rate of drug is improved；
4) lasting drug release, pharmaceutical release time is long, is better than oral medication.
Detailed description of the invention
Fig. 1 is the porosity comparison diagram of different temperatures lower bracket；
Fig. 2 is the drug release patterns of different support；
Specific embodiment
Below with reference to embodiment, explanation is further explained to embodiments of the present invention, but specific embodiment is not right
The present invention does any restriction.
Embodiment 1
1) PLGA of 0.5g is dissolved in 5ml methylene chloride；
2) mixing of 0.1gNaCl and 0.1g Ceftriaxone Sodium is weighed, is added in (1) liquid, by homogenizer, with
The revolving speed of 5000rpm stirs 5min, so that substance is evenly dispersed in a liquid；
3) PVA for weighing 2g is dissolved in 200ml deionized water；
4) (2) mixing liquid is slowly added into (3), and with the stirring of the revolving speed of 300rpm, stirs 6h；
5) after stirring, thus obtained microsphere is cleaned 5 times with deionized water, is then lyophilized, freeze-drying time is for 24 hours；
6) after being lyophilized, dry microballoon is encased in columnar mould, in 50 DEG C of baking oven inside holding 3h, after heat preservation,
Obtain carried stent.
Embodiment 2
1) PLGA of 0.5g is dissolved in 5ml methylene chloride；
2) mixing of 0.1gNaCl and 0.1g Ceftriaxone Sodium is weighed, is added in (1) liquid, by homogenizer, with
The revolving speed of 5000rpm stirs 5min, so that substance is evenly dispersed in a liquid；
3) PVA for weighing 2g is dissolved in 200ml deionized water；
4) (2) mixing liquid is slowly added into (3), and with the stirring of the revolving speed of 300rpm, stirs 6h；
5) after stirring, microballoon is cleaned 5 times with deionized water, is then lyophilized, freeze-drying time is for 24 hours；
6) after being lyophilized, dry microballoon is encased in columnar mould, in 70 DEG C of baking oven inside holding 3h, after heat preservation,
Obtain carried stent.
Embodiment 3
1) PLGA of 0.5g is dissolved in 5ml methylene chloride；
2) mixing of 0.1gNaCl and 0.1g Ceftriaxone Sodium is weighed, is added in (1) liquid, by homogenizer, with
The revolving speed of 5000rpm stirs 5min, so that substance is evenly dispersed in a liquid；
3) PVA for weighing 2g is dissolved in 200ml deionized water；
4) (2) mixing liquid is slowly added into (3), and with the stirring of the revolving speed of 300rpm, stirs 6h；
5) after stirring, microballoon is cleaned 5 times with deionized water, is then lyophilized, freeze-drying time is for 24 hours；
6) after being lyophilized, dry microballoon is encased in columnar mould, in 90 DEG C of baking oven inside holding 3h, after heat preservation,
Obtain carried stent.
Embodiment 4
Brace aperture rate comparative experiments
Every kind of bracket takes 3 Duplicate Samples, and the row's of progress alcohol method measures the porosity of bracket respectively.It is available from table 1
The average value of the porosity of bracket is 38.3771% at 50 DEG C, and the average value of the porosity of bracket is 20.9916% at 70 DEG C,
The average value of the porosity of bracket is 9.7378% at 90 DEG C.From Fig. 1 it can also be seen that as the temperature rises, the hole of bracket
Gap rate is gradually reduced.
1 different temperatures lower bracket porosity data of table
Embodiment 5
Drug release comparative test
From figure 2 it can be seen that 50 DEG C of brace aperture rate is very big, the contact to drug with body fluid is extremely advantageous, but not
The phenomenon of burst release for exempting to have drug, causes the concentration of initial stage drug to increase rapidly, damages to body.Bracket at 70 DEG C
Burst drug release phenomenon reduce, drug entirely release the stage release more uniformly.90 DEG C compared with 70 DEG C, first 15 days
Distinguish unobvious, latter 15 days as can be seen that 90 DEG C of stent drug burst size is obviously reduced.Medicine is carried when to sum up can be derived that 70 DEG C
Bracket is ideal.
The present invention is based on PLGA to have good biocompatibility, it is first prepared into porous microsphere, and principle is to make
NaCl is added during standby, by the dissolution of NaCl so that there are holes in microballoon, then microballoon is prepared by way of heating
At bracket, equally there is the presence of hole in bracket between ball and ball, further increase porosity, is conducive to the release of drug.It carries
The drug entered is Ceftriaxone Sodium, which directly acts on inflammation part, improves the utilization rate of drug, and drug is certain
Sustained release in time.
Claims (4)
1. the preparation method for the carried stent for treating cervicitis, characterized in that it comprises the following steps:
(1) PLGA of 0.5 ~ 0.8g is dissolved in 5 ~ 6ml methylene chloride；
(2) 0.1 ~ 0.15gNaCl and the mixing of 0.1 ~ 0.15g Ceftriaxone Sodium are weighed, is added in the liquid that step (1) obtains,
By homogenizer, 4 ~ 5min is stirred with the revolving speed of 4500 ~ 5000rpm, so that substance is evenly dispersed in a liquid；
(3) PVA for weighing 2 ~ 2.5g is dissolved in 200 ~ 220ml deionized water；
(4) step (2) finally obtained mixing liquid is added in the liquid that step (3) obtains, and with 250 ~ 350rpm's
Revolving speed stirring, stirs 6 ~ 8h；
(5) after stirring, thus obtained microsphere is cleaned with deionized water, is then lyophilized；
(6) after being lyophilized, dry microballoon is encased in columnar mould, in 70 DEG C of baking oven 2 ~ 3h of inside holding, after heat preservation, is obtained
To the carried stent.
2. according to claim 1 for treating the preparation method of the carried stent of cervicitis, which is characterized in that step
(5) wash number for cleaning thus obtained microsphere with deionized water is 5 ~ 8 times.
3. according to claim 1 for treating the preparation method of the carried stent of cervicitis, which is characterized in that step
(5) time of the freeze-drying is 24 ~ 36h.
4. obtained for treating the carried stent of cervicitis by any one of claim 1 ~ 3 preparation method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510707832.1A CN105327405B (en) | 2015-10-23 | 2015-10-23 | Carried stent and preparation method thereof for treating cervicitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510707832.1A CN105327405B (en) | 2015-10-23 | 2015-10-23 | Carried stent and preparation method thereof for treating cervicitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105327405A CN105327405A (en) | 2016-02-17 |
| CN105327405B true CN105327405B (en) | 2019-01-29 |
Family
ID=55278302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510707832.1A Active CN105327405B (en) | 2015-10-23 | 2015-10-23 | Carried stent and preparation method thereof for treating cervicitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105327405B (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420016D0 (en) * | 2004-09-09 | 2004-10-13 | Leuven K U Res & Dev | Controlled release oral delivery system |
| US20110212179A1 (en) * | 2008-10-30 | 2011-09-01 | David Liu | Micro-spherical porous biocompatible scaffolds and methods and apparatus for fabricating same |
| RU2627470C2 (en) * | 2012-07-16 | 2017-08-08 | Лаккуре Аб | Pharmaceutical compositions comprising oligomeric lactic acid |
| CN103212116A (en) * | 2013-04-19 | 2013-07-24 | 华南理工大学 | Method for constructing three-dimensional scaffold by polymorphous low-grade adenocarcinoma (PLGA)/calcium carbonate porous composite microsphere |
-
2015
- 2015-10-23 CN CN201510707832.1A patent/CN105327405B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105327405A (en) | 2016-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11130824B2 (en) | Method for producing hydrogels coupling high elastic modulus and absorbance | |
| Thakur et al. | Solvent induced phase inversion-based in situ forming controlled release drug delivery implants | |
| CN106750398B (en) | Carry medicine chitosan/dual cross-linked hydrogel of sodium alginate and its preparation method and application | |
| CN105517536B (en) | The sustained-release composition of injectable and its for treatment of arthritis disease and ache related method | |
| Phan et al. | Ionically cross-linked alginate-chitosan core-shell hydrogel beads for oral delivery of insulin | |
| CN102362853B (en) | Genipin cross-linked soybean protein based theophylline controlled-release gel preparation and preparation method thereof | |
| Pillay et al. | Ionotropic gelation: encapsulation of indomethacin in calcium alginate gel discs | |
| EP2485717B1 (en) | Delivery system for sustained release of a calcium-channel blocking agent | |
| CN106362223A (en) | Porous silk fibroin microneedle administration device and preparation method thereof | |
| Yassin et al. | Chitosan beads as a new gastroretentive system of verapamil | |
| CN108078911A (en) | Thermotropic hydrogel sustained release veterinary drug injection for animal contraception and preparation method thereof | |
| Iswandana et al. | Preparation of calcium alginate-tetrandrine beads using ionic gelation method as colon-targeted dosage form | |
| US9700630B2 (en) | Low molecular weight methyl cellulose-based parenteral drug delivery system | |
| CN104740641B (en) | A kind of slow control-release microsphere composition of glucose sensitive and preparation method thereof | |
| CN106667958B (en) | A kind of polypeptide sustained release microsphere agents and preparation method thereof | |
| CN105327405B (en) | Carried stent and preparation method thereof for treating cervicitis | |
| CN106377290B (en) | A kind of medicine-carried titanium nail and load medicine titanium nail and preparation method thereof | |
| KR101898816B1 (en) | Parenteral Drug Delivery System based on low Molecular Polysaccharides | |
| CN116421874A (en) | Soluble microneedle patch carrying anti-hemangioma drug and preparation method thereof | |
| Mittal et al. | Hydrogel Breakthroughs in Biomedicine: Recent Advances and Implications | |
| JP2017511371A (en) | Exenatide-containing composition and method for producing the same | |
| Kohli et al. | Ethylcellulose floating microspheres of antidiabetic agent: in vitro and in vivo evaluation | |
| CN103690993B (en) | Scaffold material capable of blood sugar induced controlled-release of drugs and used for periodontal treatment and preparation method thereof | |
| CN102058518B (en) | Self-expandable microgel pulse preparation with layer-by-layer assembled polyelectrolytes and preparation method thereof | |
| CN114762675A (en) | Controlled release type soluble rabies vaccine microneedle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |